Empowered Funds LLC Has $392,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Empowered Funds LLC lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 6.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,847 shares of the medical device company’s stock after buying an additional 335 shares during the quarter. Empowered Funds LLC’s holdings in DexCom were worth $392,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in DXCM. Taylor Frigon Capital Management LLC increased its holdings in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after acquiring an additional 11,075 shares during the last quarter. Brooktree Capital Management bought a new position in DexCom during the third quarter worth $683,000. National Pension Service increased its holdings in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Intact Investment Management Inc. bought a new position in shares of DexCom in the third quarter valued at about $650,000. Finally, Waters Parkerson & CO. LLC lifted its stake in shares of DexCom by 4.2% during the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after buying an additional 10,892 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on DXCM. Wells Fargo & Company increased their price objective on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein raised their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,431 shares of company stock worth $399,319. Company insiders own 0.30% of the company’s stock.

DexCom Stock Down 2.2 %

DXCM stock opened at $72.83 on Monday. The stock has a market capitalization of $28.45 billion, a PE ratio of 43.61, a price-to-earnings-growth ratio of 2.28 and a beta of 1.17. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The firm has a 50 day moving average of $70.61 and a 200 day moving average of $89.55.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.